To achieve climate target goals, Life Science companies need to put sustainability at the front of business decisions.

We are developing a new way to program living cells by integrating synthetic biology, computational biology, and large AI models. We focus this platform on enabling the design and manufacture of advanced therapies.

In this webinar, you will learn how our new single-use bioreactor family can help you:
– Fulfill any process strategy, be it batch, fed-batch or perfusion
– Facilitate scalability of your upstream process
– Utilize the flexible design to reduce production costs

A wide range of novel vaccine modalities and conventional approaches are used to prevent and reduce the impact of infection. Adoption of templated manufacturing processes tailored to the specific modality can optimize and accelerate production workflows.

In this On-Demand version of the presentations, key opinion leaders from

, Hileman Laboratories Singapore, Baylor College of Medicine or Biofarma, provide a fascinating story of the behind of the scenes development of the recent pandemic and how long-term collaboration to optimize a neglected tropical disease vaccine platform transformed into the COVID-19 vaccine candidates.

There is a popular board game based on a global disease outbreak that is generally rated 5 stars.  As for the real Covid-19 pandemic, it would be hard to find a single person in the Biopharma industry who would give the supply chain performance during the pandemic that kind of high review.

mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because of its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials.

mRNA technology offers many opportunities but the development and manufacturing of mRNA-based vaccines and therapeutics present a number of challenges. Learn more about the opportunities of the mRNA technology and how to overcome drug development and manufacturing challenges to bring your mRNA-based therapies to market in this first webinar.

This whitepaper describes the development and use of a cost model encompassing capital, labor, materials, consumables, and other costs, which are five key parameters of manufacturing for a variety of vaccine modalities: vaccines which use inactivated and attenuated viruses, protein subunit vaccines, virus-like particles (VLP) vaccines, Viral vector vaccines, and mRNA vaccines.

Get a step-by-step overview of the plasmid DNA manufacturing process and the challenges in pDNA downstream purification, for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications.